Core Insights - Balchem Corporation reported record financial results for the second quarter of 2025, with net sales of $255.5 million, net earnings of $38.3 million, and adjusted EBITDA of $69.2 million, reflecting strong growth across all reporting segments [1][2][4][7]. Financial Performance - Net sales increased by $21.4 million, or 9.1%, compared to the prior year quarter [7]. - GAAP net earnings rose by 19.4% to $38.3 million from $32.1 million in the prior year quarter [7]. - Adjusted EBITDA reached a record $69.2 million, an increase of 11.2% from the previous year [7]. - Diluted net earnings per share were $1.17, up from $0.98 in the prior year quarter, while adjusted earnings per share were $1.27 compared to $1.09 [7][8]. Segment Performance - The Human Nutrition and Health segment generated record sales of $160.8 million, an increase of 8.7%, with earnings from operations rising by 14.9% to $38.3 million [9]. - The Animal Nutrition and Health segment reported sales of $56.0 million, a 13.1% increase, with earnings from operations growing by 30.5% to $3.5 million [10]. - The Specialty Products segment achieved record sales of $37.2 million, a 6.0% increase, with earnings from operations slightly up by 0.4% to $11.3 million [11]. Cash Flow and Investments - Cash flows from operations were $47.3 million, with free cash flow of $40.7 million [7][14]. - The company announced plans to build a new $36 million micro-encapsulation manufacturing facility in Orange County, NY, which will more than double its capacity for micro-encapsulation technologies [7]. Market Environment - The European Commission's decision to impose provisional anti-dumping duties of 95.4% to 120.8% on choline chloride imports from China is expected to create a more competitive market environment for Balchem [4][7].